{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:06:54Z","timestamp":1793740014440,"version":"4.6.1"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The prevalence of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            causing prosthetic joint infection (PJI) supports investigation of higher doses of daptomycin in the management of PJI. This was a prospective, randomized controlled trial studying safety and efficacy of daptomycin (6 and 8 mg\/kg of body weight) compared with standard-of-care therapy for PJI. This open-label study randomized 75 patients undergoing 2-stage revision arthroplasty to daptomycin at 6 or 8 mg\/kg or a comparator (vancomycin, teicoplanin, or semisynthetic penicillin). After prosthesis removal, patients received 6 weeks of antibiotic treatment and a 2- to 6-week antibiotic-free period before implantation of a new prosthesis. Test of cure (TOC) was within 1 to 2 weeks after reimplantation. The primary objective was evaluation of creatine phosphokinase (CPK) levels. Secondary objectives were clinical efficacy and microbiological assessments. Of 73 CPK safety population patients, CPK elevation of &gt;500 U\/liter occurred in 4 of 25 (16.0%) (daptomycin, 6 mg\/kg) and 5 of 23 (21.7%) (daptomycin, 8 mg\/kg) daptomycin-treated patients and 2 of 25 (8.0%) comparator patients. Adverse-event rates were similar among daptomycin and comparator groups. Among modified intent-to-treat patients at TOC, clinical success rates were 14 of 24 (58.3%) for 6 mg\/kg daptomycin, 14 of 23 (60.9%) for 8 mg\/kg daptomycin, and 8 of 21 (38.1%) for the comparator. Overall microbiological success at TOC was 12 of 24 (50.0%) for 6 mg\/kg daptomycin, 12 of 23 (52.2%) for 8 mg\/kg daptomycin, and 8 of 21 (38.1%) for comparator patients. In conclusion, daptomycin at 6 and 8 mg\/kg given for up to 6 weeks was safe and appeared to be effective in managing staphylococcal PJI using a 2-stage revision arthroplasty technique in a total of 49 patients.\n          <\/jats:p>","DOI":"10.1128\/aac.00038-12","type":"journal-article","created":{"date-parts":[[2012,8,21]],"date-time":"2012-08-21T04:22:25Z","timestamp":1345522945000},"page":"5626-5632","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":86,"title":["Randomized Controlled Trial of the Safety and Efficacy of Daptomycin versus Standard-of-Care Therapy for Management of Patients with Osteomyelitis Associated with Prosthetic Devices Undergoing Two-Stage Revision Arthroplasty"],"prefix":"10.1128","volume":"56","author":[{"given":"Ivor","family":"Byren","sequence":"first","affiliation":[{"name":"Nuffield Orthopaedic Centre, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruta","family":"Rege","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Campanaro","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Yankelev","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady","family":"Kuropatkin","sequence":"additional","affiliation":[{"name":"Samara Regional Clinical Hospital, Samara, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Evans","sequence":"additional","affiliation":[{"name":"UAMS College of Medicine, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.idc.0000206490.05422.df"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.5580\/1479"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp469"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00247-06"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/514991"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.4.414"},{"key":"e_1_3_2_8_2","unstructured":"Cubist Pharmaceuticals. 2010. Cubicin \u00ae (daptomycin for injection) [prescribing information]. Cubist Pharmaceuticals Inc. Lexington MA."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035415"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/600039"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X74961"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp177"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/17453670902805064"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01854.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.07.010"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2004.09.009"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16727-5"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.5.689"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2006.02.156"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.273.24.1950"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00402-008-0772-x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-008-0480-4"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2005.07.010"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.blo.0000084401.53464.4b"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/321863"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040181"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00038-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00038-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:01:48Z","timestamp":1645480908000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00038-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1128\/AAC.00038-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00038-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"2012-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}